Ironwood Pharmaceuticals
IRWD
226 hedge funds and large institutions have $567M invested in Ironwood Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 86 increasing their positions, 56 reducing their positions, and 25 closing their positions.
1,845% more call options, than puts
Call options by funds: $40.7M | Put options by funds: $2.09M
124% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 25
54% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 56
14% more funds holding
Funds holding: 199 → 226 (+27)
9% more capital invested
Capital invested by funds: $520M → $567M (+$46.5M)
3.96% more ownership
Funds ownership: 95.06% → 99.02% (+4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12.5M |
| 2 |
Two Sigma Investments
New York
|
+$12.3M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$12.2M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$11.5M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$27.6M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$11.6M |
| 3 |
Jane Street
New York
|
-$9.01M |
| 4 |
AC
Armistice Capital
New York
|
-$4.09M |
| 5 |
Lazard Asset Management
New York
|
-$2.91M |
IRWD Hedge Fund Activity: Q1 2026 in Review
226 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2026, worth a combined $567M — up 8.9% from $520M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new IRWD positions and 25 closed out — a net gain of 31 holders — while 86 added to existing stakes and 56 trimmed.
The largest buyer was State Street, adding an estimated $12.5M. The largest seller was Sarissa Capital Management, cutting an estimated $27.6M.
- 226 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2026, up from 199 in Q4 2025.
- Funds reported $567M of Ironwood Pharmaceuticals stock for Q1 2026, up 8.9% quarter-over-quarter.
- 56 funds opened new Ironwood Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +31 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2026 was State Street, an estimated $12.5M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2026 was Sarissa Capital Management, an estimated $27.6M sold.
Based on aggregated 13F filings for Q1 2026.